Federal circuit court ruling Quincy referenced in motion for reconsideration of jury’s verdict on New York state laws “offers nothing so Olympian,” New York federal district court says. Decision clears way for FTC to continue its separate litigation in same court.

ODS recently published request for comments on 2025-2029 draft strategic plan, “Blueprint for a Coordinated Dietary Supplement Research Agenda at NIH.” Publication of draft for ODS’s first five-year plan since 2017-2021 corresponds with having its first permanent director since 2022.

UK regulator the Food Standards Agency intends to assess the risks associated with consuming supplements containing ashwagandha and to determine whether a safe level of the herb can be established. The launch of the consultation follows warnings from regulators across Europe about the safety of ashwagandha, with its consumption linked to a number of adverse health effects.

Noting similar warnings a year ago, the FDA and FTC announce warnings to six more, part of a joint effort to stop sales of copycat food products containing delta-8 THC, saying companies selling these "illegal products are demonstrating complete neglect for consumer safety.”

Committee’s report published with FY2025 appropriation states a different approach to establishing FDA regulation of non-drug products containing hemp as a derivative of cannabis de-scheduled as controlled substance in the US since 2018.

“Science is pretty evident that there's no connection between supplement use and eating disorders,” says NPA’s Kyle Turk. “CRN continues to raise fundamental concerns about what benefit the bill offers,” says CRN’s Steve Mister.